{"groups":[{"description":"Relapsed or refractory myeloma patients.","id":"FG000","title":"AUTO2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Progressive disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"Leukaperesed"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Started Pre-conditioning Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Received Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Screening procedures were performed up to 12 weeks before study treatment administered","recruitmentDetails":"Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients were treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells."}